Equity Overview
Price & Market Data
Price: $5.97
Daily Change: $0.00 / 0.00%
Daily Range: $5.91 - $6.29
Market Cap: $476,439,040
Daily Volume: 24,472
Performance Metrics
1 Week: 11.04%
1 Month: -2.86%
3 Months: 75.19%
6 Months: 105.3%
1 Year: 125.4%
YTD: 67.34%
Company Details
Employees: 55
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.